Extension Study to Evaluate the Long-term Outcomes of Subjects Following CLS-AX Administration for Age-related Macular Degeneration in the CLS-AX CLS1002-101 Study
Conditions: Neovascular Age-related Macular Degeneration
Sponsor: Clearside Biomedical, Inc.

Compound Name: 
CLS-AX, axitinib injectable suspension 
Protocol Number: 
CLS1002-102 
IND Number: 
132228 
NCT Number: 
NCT05131646 
Protocol Title 
Extension study to evaluate the long-term outcomes of 
subjects following CLS-AX administration for age-related 
macular degeneration in the CLS-AX CLS1002-101 study 
Sponsor: 
Clearside Biomedical, Inc. 
900 North Point Parkway, Suite 200 
Alpharetta, GA 30005 
Issue Date: 
Protocol Amendment 1 Date: 
20 July 2021 
26 January 2022 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 
Clinical Protocol
Amendment 1 Summary of Changes 
26 January 2022 
Page 1 of 13 
CONFIDENTIAL
A.
SUMMARY OF CHANGES
Protocol Amendment 1
Protocol Title:
OASIS EXTENSION: EXTENSION STUDY TO EVALUATE THE LONG-TERM OUTCOMES OF 
SUBJECTS FOLLOWING CLS-AX ADMINISTRATION FOR AGE-RELATED MACULAR 
DEGENERATION IN THE CLS-AX CLS1002-101 STUDY 
Protocol Number:
IND:
CLS1002-102 
132228 
Original Version Date: 
20 July 2021 
Amendment Number:
1
Version Number and Date:
Version 2, 26 January 2022 
Note: for clarity, deleted text will be denoted with a strikethrough and additional/altered text will appear in bold. 
Minor editorial changes to improve readability will not be documented.

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 1 of 60 
CONFIDENTIAL
Project: 
1002 
Compound Number/Name:
CLS-AX (axitinib injectable suspension)  
Protocol Number: 
CLS1002-102 
IND Number:
132228 
Phase:
Non-Interventional 
Protocol Title: 
EXTENSION STUDY TO EVALUATE THE LONG-TERM 
OUTCOMES OF SUBJECTS FOLLOWING CLS-AX 
ADMINISTRATION FOR AGE-RELATED MACULAR 
DEGENERATION IN THE CLS-AX CLS1002-101 STUDY 
Sponsor:
Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200 
Alpharetta, GA 30005 
Primary Medical Monitor:
Benjamin I. Rubin, M.D. 
Principal Investigator:
To be appointed before the end of the study
Protocol Amendment 1 Date: 
Issue Date:
26 January 2022
20 July 2021 
CONFIDENTIAL
This protocol contains confidential information about a product provided by Clearside Biomedical, Inc.  
This information is provided for the exclusive use of the Investigators participating in this study.  Any 
and all confidential information contained herein may not be disclosed to any other person or party 
without the prior written consent of Clearside Biomedical, Inc. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 2 of 60 
CONFIDENTIAL
SIGNATURE PAGE
This study protocol has been reviewed and approved by the undersigned persons. It is confirmed 
that the information and guidance given in this protocol complies with scientific principles, the 
guidelines of Good Clinical Practices, the Declaration of Helsinki in the latest relevant version 
and the applicable legal and regulatory requirements. 
Sponsor Signatory:
Thomas Ciulla, M.D.
Chief Medical Officer
Clearside Biomedical, Inc.
ELECTRONIC SIGNATURE 
ON FILE
Sponsor Signatory:
Barbara Bauschka
Vice President, Regulatory Operations
Clearside Biomedical, Inc.
ELECTRONIC SIGNATURE 
ON FILE
Sponsor Signatory:
Colette Hall, M.D.
Vice President, Medical and Safety
Clearside Biomedical, Inc.
ELECTRONIC SIGNATURE 
ON FILE

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 3 of 60 
CONFIDENTIAL
INVESTIGATOR’S AGREEMENT
I have received and read the Investigator’s Brochure for CLS-AX (axitinib injectable 
suspension).  I have read the CLS1002-102 Protocol and agree to conduct the study as outlined.  
I agree to maintain the confidentiality of all information received or developed in connection 
with this protocol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Printed Name of Investigator 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Investigator 
 
 
 
 
 
 
 
Date

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 4 of 60 
CONFIDENTIAL
PROCEDURES IN CASE OF EMERGENCY
Table 1: 
Emergency Contact Information 
Role in Study
Name
Address and Telephone 
number
Clinical Study Leader 
Georgina Debrah
Clearside Biomedical, Inc.
900 North Point Parkway, 
Suite 200, 
Alpharetta, GA 30005 
USA
(678) 254-2345 
Responsible Physician
Thomas Ciulla, M.D. 
Clearside Biomedical, Inc.
900 North Point Parkway, 
Suite 200, 
Alpharetta, GA 30005 
USA
(678) 392-2318 
Drug Safety Physician 
Colette Hall, M.D. 
Clearside Biomedical, Inc.
900 North Point Parkway, 
Suite 200, 
Alpharetta, GA 30005 
USA
(678) 820-4178 
24-Hour Emergency Contact 
Benjamin I. Rubin, M.D. 
MedTrials, Inc.
7801 Renoir Court, 
Potomac, MD 
USA
(301) 509-4451 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 5 of 60 
CONFIDENTIAL
CLINICAL LABORATORIES AND MEDICAL INSTITUTIONS
Table 2: 
Names and Addresses of Institutions
Reading Center
Name and Address
Central Reading Center for Fundus Photographs, Fluorescein 
Angiograms and Spectral Domain Optical Coherence 
Tomography 
Merit CRO, Inc. 
6527 Normandy Lane 
 #100 
Madison, Wisconsin 53719
USA

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 6 of 60 
CONFIDENTIAL
REVISION HISTORY
Table 3: 
Revision History
Version Number
Date
Revision summary 
1.0
20 July 2021 
Initial release of protocol.
2.0
26 Jan 2022 
Protocol Amendment 1. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 7 of 60 
CONFIDENTIAL
2.
SYNOPSIS
Name of Sponsor/Company:
Clearside Biomedical, Inc.
Name of Investigational Product:
CLS-AX (axitinib injectable suspension) 
Name of Active Ingredient:
Axitinib
Title of Study: 
Extension study to evaluate the long-term outcomes of subjects following CLS-AX administration for 
age-related macular degeneration in the CLS-AX CLS1002-101 study 
Study center(s): Multi-center
Principal Investigator: Multi-Center
Studied period: 12 Week Duration  
Estimated date first patient enrolled: Oct 2021 
Estimated date last patient completed: December 2022 
Phase of development: 
Non-interventional study 
Background and Rationale:
Currently, anti-vascular endothelial growth factor (VEGF)-A drugs are the standard of care for the 
treatment of neovascular age-related macular degeneration (nAMD) (Flaxel, 2020); however, an 
unmet need remains for significantly improving and maintaining visual acuity in most patients 
(Rofagha, 2013, CATT, 2016, Singer, 2012).
Axitinib demonstrates intrinsic high potency and achieves pan-VEGF inhibition through tyrosine 
kinase receptor blockade (INLYTA, 2018, Hu-Lowe, 2008); axitinib is a second-generation tyrosine 
kinase inhibitor (TKI) that potently inhibits vascular endothelial growth factor receptors VEGFR-1, 
VEGFR-2, and VEGFR-3 at picomolar concentrations, and inhibits platelet-derived growth factor 
receptors (PDGFR) and c-KIT receptors to a significantly lesser degree, by stabilizing the receptor 
kinase domain in an inactive conformation. In preclinical work by independent investigators, axitinib 
effectively inhibited corneal, retinal and choroidal angiogenesis in multiple preclinical models 
(Riquelme, 2018, Yuan, 2015, Giddabasappa, 2016, Nakano, 2016, Kang, 2013).  Topical axitinib 
more effectively inhibited experimental corneal neovascularization than other topical tyrosine kinase 
receptor inhibitors in a preclinical model (Yuan, 2015).  Furthermore, experimental oral axitinib not 
only inhibited choroidal neovascularization, but also caused regression of established 
neovascularization (Kang, 2013). Importantly, in-vitro assessment has revealed better 
biocompatibility with ocular cells than other tyrosine kinase inhibitors (Thiele, 2013).
Suprachoroidal (SC) injection is a novel drug-dispensing approach that is a minimally invasive office-
based procedure, performed using Clearside’s proprietary injection device, the SCS Microinjector®. A 
SC injection is the term used to describe this intraocular injection procedure performed in the pars 
plana approximately 4 – 4.5 mm posterior to the limbus, resulting in a sub-scleral dispensing of drug 
product into the suprachoroidal space (SCS) which is the transition region between the sclera and the 
choroid.  Immediately after the SC injection procedure, injectate moves posteriorly from the site of 
the injection, with the fluid being absorbed dominantly into the inner sclera, choroid, retinal pigment 
epithelial (RPE) cells, and retina. Clearside Biomedical Inc. (“Clearside”) is developing a proprietary 
formulation of axitinib, CLS-AX (axitinib injectable suspension) to treat nAMD by injection into the 
SCS. Utilizing this approach enables nearly direct access to the tissue layers affected in nAMD, i.e., 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 9 of 60 
CONFIDENTIAL
Each cohort will be assessed for safety and tolerability as well as for effects on visual function and 
ocular anatomy as outlined in the time and events schedule (Section 20). 
Number of patients (planned): A maximum of 19 subjects.
Diagnosis and main criteria for inclusion: 
Subject eligibility will be determined on the Enrollment Day which will be on the same day as the 
final visit (Visit 5) of the Parent study after the subject has exited the Parent study, or no later than 
within 48 hours of exiting the Parent Study.
Inclusion criteria:
Subjects are eligible for participation in this study if s/he meets all of the following criteria:
1.
Enrolled in and completed the Parent study, CLS1002-101, as part of Cohort 2, Cohort 3 or 
Cohort 4. 
2.
Understands the language of the informed consent; willing and able to provide written 
informed consent prior to any study procedures; willing to comply with the instructions and 
attend all scheduled study visits.
3.
Subjects of childbearing potential must agree to use acceptable methods of contraception 
throughout participation in the study.  Acceptable methods of contraception include double 
barrier methods (condom with spermicide or diaphragm with spermicide), hormonal methods 
(oral contraceptives, implantable, transdermal, or injectable contraceptives), or an intrauterine 
contraceptive device with a documented failure rate of less than 1% per year.  Abstinence 
may be considered an acceptable method of contraception at the discretion of the Investigator, 
but the subject must agree to use one of the acceptable birth control methods if he or she 
becomes sexually active.  Females of childbearing potential must consent to performance of a 
pregnancy test.
Exclusion criteria:
Subjects are ineligible for participation in this study if s/he meets any of the following criteria:
1.
2.
Enrolled in the Parent study CLS1002-101 as part of Cohort 1.
3.
Females of childbearing potential who are pregnant and or lactating.
Investigational product, dosage, and mode of administration:  
No investigational product will be administered in this study.
Reference therapy, dosage, and mode of administration: None. 
Criteria for evaluation: 
Primary: Number of subjects experiencing adverse events and serious adverse events, grouped by 
organ class and preferred term, relatedness to study treatment, and severity.
Secondary: Incidence/descriptive statistics of changes in ocular safety parameters, visual function 
and ocular anatomy, and the need for additional treatment for nAMD.
Statistical methods:

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 12 of 60 
CONFIDENTIAL
3.
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES  
TABLE OF CONTENTS
1. 
TITLE PAGE................................................................................................................1 
INVESTIGATOR’S AGREEMENT...............................................................................................3 
PROCEDURES IN CASE OF EMERGENCY...............................................................................4 
2. 
SYNOPSIS ...................................................................................................................7 
3. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES ...............12 
4. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.............................17 
5. 
INTRODUCTION ......................................................................................................19 
6. 
TRIAL OBJECTIVES AND PURPOSE ....................................................................23 
6.1. 
Primary Objective .......................................................................................................23 
6.2. 
Secondary Objectives .................................................................................................23 
7. 
INVESTIGATIONAL PLAN .....................................................................................24 
7.1. 
Overall Study Design ..................................................................................................24 
7.2. 
Endpoints ....................................................................................................................25 
7.2.1. 
Primary Endpoint ........................................................................................................25 
7.2.2. 
Secondary Endpoints ..................................................................................................25 
7.3. 
Number of Subjects ....................................................................................................26 
7.4. 
Treatment Assignment ................................................................................................26 
7.5. 
Criteria for Study Termination ...................................................................................26 
7.5.1. 
Early Discontinuation of the Study.............................................................................26 
7.5.2. 
Suspension of the Study..............................................................................................26 
8. 
SELECTION AND WITHDRAWAL OF SUBJECTS ..............................................27 
8.1. 
Subject Inclusion Criteria ...........................................................................................27 
8.2. 
Subject Exclusion Criteria ..........................................................................................27 
8.3. 
Subject Withdrawal Criteria .......................................................................................27 
8.4. 
Visit Procedure Description ........................................................................................28 
8.4.1. 
General Procedures .....................................................................................................28 
8.4.2. 
Enrollment Day (0 – 48 hours post Visit 5) ................................................................29 
8.4.2.1. 
Enrollment Day - Additional Therapy ........................................................................29 
8.4.2.2. 
Enrollment Day - Post Administration of Additional Therapy ..................................29 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 13 of 60 
CONFIDENTIAL
8.4.3. 
Visits 6 and 7 (Weeks 16 and 20) ...............................................................................30 
8.4.3.1. 
Visits 6 and 7 (Weeks 16 and 20) - Additional Therapy ............................................31 
8.4.3.2. 
Visits 6 and 7 (Weeks 16 and 20) - Post Administration of Additional 
Therapy .......................................................................................................................31 
8.4.4. 
Visit 8 (Week 24) End of Study/Early Termination ...................................................31 
8.4.5. 
Unscheduled Visits .....................................................................................................32 
9. 
TREATMENT OF SUBJECTS ..................................................................................33 
9.1. 
Treatment Regimen, Dosing, and Duration ................................................................33 
9.2. 
Study Eye Determination ............................................................................................33 
9.3. 
Fellow Eye Treatment .................................................................................................33 
9.4. 
Additional Treatment ..................................................................................................33 
9.4.1. 
Additional Therapy Criteria ........................................................................................33 
9.5. 
Concomitant Medications ...........................................................................................34 
9.5.1. 
Prohibited Medications ...............................................................................................34 
9.6. 
Treatment Compliance ................................................................................................35 
9.7. 
Randomization and Masking ......................................................................................35 
10. 
STUDY DRUG MATERIALS AND MANAGEMENT ...........................................36 
11. 
ASSESSMENT OF SAFETY .....................................................................................37 
11.1. 
Safety Variables ..........................................................................................................37 
11.1.1. 
Best Corrected Visual Acuity .....................................................................................37 
11.1.2. 
Spectral Domain Optical Coherence Tomography .....................................................37 
11.1.3. 
Intraocular Pressure ....................................................................................................37 
11.1.4. 
Slit-lamp Biomicroscopy ............................................................................................38 
11.1.4.1. 
Cataract Lens Grading ................................................................................................38 
11.1.4.2. 
Anterior Chamber Cells ..............................................................................................38 
11.1.4.3. 
Anterior Chamber Flare ..............................................................................................39 
11.1.5. 
Indirect Ophthalmoscopy ............................................................................................39 
11.1.5.1. 
Vitreous Haze .............................................................................................................39 
11.1.6. 
Fluorescein Angiography ............................................................................................40 
11.1.7. 
Fundus Photography ...................................................................................................40 
11.1.8. 
Vital Signs ..................................................................................................................40 
11.1.9. 
Review of Body Systems (Physical Examination) .....................................................40 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 14 of 60 
CONFIDENTIAL
11.1.9.1. 
Pregnancy Screen ........................................................................................................41 
11.2. 
Adverse and Serious Adverse Events .........................................................................41 
11.2.1. 
Definition of Adverse Events .....................................................................................41 
11.2.1.1. 
Adverse Event (AE) ....................................................................................................41 
11.2.1.2. 
Abnormal Clinical Assessments as Adverse Events and Serious Adverse 
Events .........................................................................................................................41 
11.2.1.3. 
Serious Adverse Event (SAE) ....................................................................................42 
11.2.2. 
Evaluating Adverse Events .........................................................................................42 
11.2.2.1. 
Intensity/Severity Grade .............................................................................................42 
11.2.2.2. 
Assessment of Causality .............................................................................................43 
11.2.3. 
Recording Adverse Events .........................................................................................43 
11.2.4. 
Reporting Adverse Events ..........................................................................................44 
11.2.5. 
Follow-up of AEs and SAEs .......................................................................................44 
11.2.6. 
Exposure in utero During Clinical Trials ...................................................................45 
11.2.7. 
Complaint Handling ....................................................................................................46 
12. 
STATISTICS ..............................................................................................................47 
12.1. 
Randomization ............................................................................................................47 
12.2. 
Determination of Sample Size and Level of Significance ..........................................47 
12.3. 
Subject Disposition and Demographic and Baseline Characteristics .........................47 
12.4. 
Analysis Populations ..................................................................................................47 
12.4.1. 
Safety Population ........................................................................................................47 
12.5. 
Analysis Methods .......................................................................................................47 
12.5.1. 
Schedule of Analyses ..................................................................................................48 
12.5.2. 
Safety Analysis ...........................................................................................................48 
12.5.3. 
Secondary Safety Analyses .........................................................................................49 
12.5.4. 
Subgroup Analysis ......................................................................................................49 
12.5.5. 
Interim Analysis ..........................................................................................................49 
12.5.6. 
Pharmacodynamic Analysis........................................................................................49 
12.5.7. 
Pharmacokinetic Analysis ..........................................................................................49 
12.5.8. 
Procedure for Accounting for Missing Data ...............................................................49 
13. 
DIRECT ACCESS TO SOURCE DATA/DOCUMENTS.........................................50 
13.1. 
Study Monitoring ........................................................................................................50 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 15 of 60 
CONFIDENTIAL
13.2. 
Audits and Inspections ................................................................................................50 
13.3. 
Institutional Review Board (IRB) ...............................................................................50 
14. 
QUALITY CONTROL AND QUALITY ASSURANCE .........................................51 
15. 
ETHICS ......................................................................................................................52 
15.1. 
Ethics Review .............................................................................................................52 
15.2. 
Ethical Conduct of the Study ......................................................................................52 
15.3. 
Written Informed Consent ..........................................................................................52 
16. 
DATA HANDLING AND RECORDKEEPING .......................................................54 
16.1. 
Case Report Forms/Electronic Data Record ...............................................................54 
16.2. 
Inspection of Records .................................................................................................54 
16.3. 
Retention of Records ..................................................................................................54 
17. 
FINANCING AND INSURANCE .............................................................................55 
17.1. 
Finance ........................................................................................................................55 
17.2. 
Insurance .....................................................................................................................55 
18. 
PUBLICATION POLICY ..........................................................................................56 
19. 
REFERENCES ...........................................................................................................57 
20. 
APPENDICES ............................................................................................................60 
APPENDIX A: TIME AND EVENTS SCHEDULE .................................................................60 
.

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 16 of 60 
CONFIDENTIAL
LIST OF TABLES
Table 1: 
Emergency Contact Information ...................................................................................4 
Table 2: 
Names and Addresses of Institutions ............................................................................5 
Table 3: 
Revision History ...........................................................................................................6 
Table 4: 
Abbreviations and Specialist Terms ...........................................................................17 
Table 5: 
Anterior Chamber Cells Grading Scale ......................................................................38 
Table 6: 
Anterior Chamber Flare Grading Scale ......................................................................39 
Table 7: 
Scale for Determining Degree of Vitreous Haze ........................................................39 
Table 8: 
CTCAE Intensity Grades ............................................................................................42 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 17 of 60 
CONFIDENTIAL
4.
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
The following abbreviations and specialist terms are used in this study protocol. 
Table 4: 
Abbreviations and Specialist Terms
Abbreviation or Specialist Term
Explanation 
ADL
Activities of daily living
AE
Adverse event 
AMD
Age-related macular degeneration
Baseline
Visit 2 (Baseline, Day 1) of the Parent study, CLS1002-101
BCVA
Best corrected visual acuity
BSS
Balanced saline solution
CNV
Choroidal neovascularization
CRF
Case report form
CST
Central subfield retinal thickness 
CTCAE
Common Terminology Criteria for Adverse Events 
ETDRS
Early Treatment Diabetic Retinopathy Study 
GCP
Good Clinical Practice
GLP
Good Laboratory Practice 
IB4
isolectin B4
IC50
50% inhibitory concentration
ICH
International Conference on Harmonization 
IEC
Independent Ethics Committee 
IOP
Intraocular pressure 
IRB
Institutional Review Board 
IVT
Intravitreal(ly)
LLOQ
Lower Limit of Quantification
LOC III
Lens Opacities Classification System III
nAMD
Neovascular age-related macular degeneration
NCI
National Cancer Institute
MedDRA
Medical Dictionary for Regulatory Applications 
Parent study 
OASIS, CLS1002-101 Study 
PD
Pharmacodynamics 
PDGFR 
Platelet-derived growth factor receptor

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 18 of 60 
CONFIDENTIAL
Table 4: 
Abbreviations and Specialist Terms (Continued)
Abbreviation or Specialist Term
Explanation 
PK
Pharmacokinetics
PRN
Pro re nata; “when necessary”
RPE
Retinal pigment epithelial
SAE
Serious adverse event
SC
Suprachoroidal 
SCS
Suprachoroidal space 
SD-OCT
Spectral Domain Optical Coherence Tomography
SOC
Systemic organ class
TEAE
Treatment-emergent adverse event
TK
Toxicokinetic 
TKI
Tyrosine kinase inhibitor
VA
Visual acuity
VEGF
Vascular endothelial growth factor 
VEGFR
Vascular endothelial growth factor receptor

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 19 of 60 
CONFIDENTIAL
5.
INTRODUCTION
In developed countries, neovascular age-related macular degeneration (nAMD) is the leading 
cause of irreversible central blindness (Congdon, 2004, The Eye Diseases Prevalence Research 
Group, 2004, Wong, 2014). Age-related macular degeneration (AMD) pathogenesis is complex 
and still not fully understood. However, many of the mechanisms involved are already partially 
known and, specifically for the 10-15% of AMD classified as the neovascular type, include the 
vascular endothelial growth factor (VEGF) signaling pathway. In nAMD, abnormal blood vessel 
growth results in choroidal neovascularization (CNV) in the choriocapillaris, a layer of 
capillaries situated immediately below Bruch’s membrane, under the retina and macula. 
Choroidal neovascularization leads to the leakage of blood, lipids, and serum into the retinal 
layers and causes the macula to bulge or lift up from its normal position, distorting or destroying 
central vision (Ambati, 2003). In nAMD, VEGF-A, which acts at VEGF receptors 1 and 2 
(VEGFR-1, VEGFR-2), has been shown to promote abnormal blood vessel growth and is 
therefore an appropriate target for treatment.
Currently, anti-VEGF-A drugs are the standard of care for the treatment of nAMD (Flaxel,
2020); however, an unmet need remains for significantly improving and maintaining visual 
acuity in most patients (Rofagha, 2013, CATT, 2016, Singer, 2012). Specifically, there may be a 
ceiling of efficacy with current anti-VEGF-A agents, as increased anti-VEGF-A dosage or more 
intense regimens yield no additional best corrected visual acuity (BCVA) benefit (Heier, 2012,
Busbee, 2013, Schmidt-Erfurth , 2014).  Recent data on VEGF regulation may be relevant, as 
anti-VEGF-A therapy has been shown to upregulate other members of the VEGF family in both 
macular degeneration (Cabral, 2018) and colon cancer patients (Lieu, 2013); this secondary 
upregulation of other members of the VEGF family may account for "resistance" to VEGF-A
therapy (Lieu, 2013).  Furthermore, the current treatment paradigm of frequent intravitreal (IVT) 
injections is burdensome. For example, recent large “real-world” retrospective studies of nAMD 
demonstrated that patients are undertreated receiving only 6 to 7 injections on average, yielding 
only a mean of 1 to 3 letters gained in BCVA one year after initiation of treatment (Ciulla, 2020,
Rao, 2018).
Axitinib demonstrates intrinsic high potency and achieves pan-VEGF inhibition through tyrosine 
kinase receptor blockade (INLYTA, 2018, Hu-Lowe, 2008); it is a second-generation tyrosine 
kinase inhibitor (TKI) that inhibits vascular endothelial growth factor receptors VEGFR-1, 
VEGFR-2, and VEGFR-3 at picomolar concentrations, and inhibits platelet-derived growth 
factor receptors (PDGFR) and c-Kit receptors to a significantly lesser degree, by stabilizing the 
receptor kinase domain in an inactive conformation. Axitinib is currently approved in an oral 
tablet formulation (INLYTA®) for the treatment of advanced renal cell carcinoma after failure of 
1 prior systemic therapy. In preclinical work by independent investigators, axitinib has shown 
promising results in animal models of ocular angiogenesis. Specifically, it effectively inhibited 
corneal, retinal and choroidal angiogenesis in multiple preclinical models (Riquelme, 2018,
Yuan, 2015, Giddabasappa, 2016, Nakano, 2016, Kang, 2013). Topical axitinib more effectively 
inhibited corneal neovascularization than other topical tyrosine kinase receptor inhibitors in a 
preclinical model (Yuan, 2015). Furthermore, oral axitinib not only inhibited choroidal 
neovascularization, but also caused regression of established neovascularization in a preclinical 
model (Kang, 2013), a highly desired therapeutic effect for the treatment of human nAMD. In a 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 20 of 60 
CONFIDENTIAL
cell culture study, axitinib consistently exhibited superior cell viability among five different 
ocular cell lines, even under conditions of oxidative stress, compared to other tyrosine kinase 
inhibitors previously assessed in nAMD clinical trials (Thiele, 2013).
Clearside Biomedical Inc. (“Clearside”) is developing a proprietary formulation of axitinib, 
CLS-AX (axitinib injectable suspension) to treat nAMD by injection into the suprachoroidal 
space (SCS). Suprachoroidal (SC) injection is a novel drug-dispensing approach that employs the 
SCS Microinjector®, a proprietary piston syringe and a needle approximately 1 mm in length. A 
SC injection is the term used to describe this intraocular injection procedure performed in the 
pars plana approximately 4 - 4.5 mm posterior to the limbus, resulting in sub scleral dispensing 
of drug product into the SCS which is the transition region between the sclera and the choroid. 
Immediately after the SC injection procedure, injectate moves posteriorly from the site of the
injection, with the fluid being absorbed dominantly into the inner sclera, choroid, retinal pigment 
epithelial (RPE) cells, and retina (based on animal models). Suprachoroidal injection of CLS-
AX, with a resulting ocular distribution of CLS-AX in high amounts into the choroid, RPE cells, 
and retina (based on data from animal models) provides the potential for robust and sustained 
efficacy outcomes in patients with nAMD. While there is high exposure to CLS-AX in the retina, 
RPE cells, and choroid, there is also lower exposure to CLS-AX in the anterior segment and the 
lens, providing the potential for a reduced incidence of ocular adverse events. Systemic levels of 
axitinib following SC injection are low to below the limits of quantification. Further, these 
systemic levels of axitinib are vastly below levels observed following oral administration of 
axitinib.
Suprachoroidal injection with Clearside’s SCS Microinjector has been evaluated in humans in 
the Sponsor’s clinical development program for an ocular corticosteroid (triamcinolone 
acetonide injectable suspension, CLS-TA). Suprachoroidal injections may be associated with 
increased ocular pressure at the time of injection, therefore subjects should be appropriately 
assessed following completion of the suprachoroidal injection. Additionally, risks of ocular 
toxicity and/or inflammation have been mitigated through the single dose escalation design of 
this clinical trial, with an initial dose based on preclinical toxicology studies in two species. 
Procedural risks, such as hemorrhage, infection, ocular hypertension, and retinal tear or 
detachment, have been assessed to be low and acceptable in previous clinical studies with CLS-
TA, which have utilized the identical injector design in over 1000 injection procedures. 
Nonclinical pharmacodynamic (PD) studies demonstrate reduced fluorescein leakage and 
reduced growth of new blood vessels after SC injection of CLS-AX, while pharmacokinetic (PK) 
studies demonstrate durability via SC injection, supporting the potential to reduce treatment 
burden associated with frequent IVT injections. 
x
In a laser-induced porcine model of CNV, 8 pigs were administered SC injections of 4 
mg of CLS-AX in the right eye and balanced salt solution (BSS) in the left eye. At 1 and 
2 weeks after the laser-induced injury, the eyes treated with CLS-AX had a significantly 
smaller mean area of fluorescence compared to the BSS-treated eyes (P<0.009).  
Quantification of neovascularization was performed on retinal flat mount tissue by 
measuring the isolectin B4 (IB4) signal. This analysis revealed that eyes treated with 
CLS-AX had significantly lower IB4 signal than BSS treated eyes (P=0.0297). 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 21 of 60 
CONFIDENTIAL
x
Similar results were obtained in a rat laser induced CNV model following SC injections 
of CLS-AX once weekly for 2 weeks. Decreases in the incidence of clinically important 
lesions (scores of 3 or 4) were noted in animals given 0.4 mg/eye CLS-AX, where 8/20 
eyes (40%) showed a general improvement (scores of 0 to 2) and attained statistical 
significance by Day 21, compared to 2/20 eyes (10%) receiving control (saline). These 
results indicate that SC injection of CLS-AX significantly reduced fluorescein leakage 
and growth of new blood vessels at the site of the retinal laser lesion as compared to 
saline treatment.
With respect to PK, a 10-week study was performed in pigmented Dutch Belted rabbits to 
determine ocular tissue distribution after a single SC administration of CLS-AX. The injection 
was well tolerated. Retinal levels were maintained above the in vitro 50% inhibitory 
concentration (IC50) with a SC injection of CLS-AX at 0.03 mg/eye and at 0.1 mg/eye for the 
entire duration of the study. 
Systemic absorption of axitinib following SC administration of CLS-AX was assessed in two 
non- Good Laboratory Practice (GLP) compliant 2-week single dose tolerability studies (with 
toxicokinetics (TK)) in rabbits and monkeys, one GLP compliant 4-week single dose toxicity 
studies in rabbits (with TK and a 26-week recovery period), and one GLP compliant 4-week 
single dose toxicity study in monkeys (with TK); all by SC injection. Plasma from blood 
collected from rabbits and monkeys during the conduct of 4-week toxicity studies was analyzed 
using an LC-MS/MS method. The lower limit of quantification (LLOQ) was 2 ng/mL in both 
species.
x
In the 2-week single dose rabbit toxicity study, CLS-AX was administered as a single 
XQLODWHUDO6&LQMHFWLRQȝ/ULJKWH\HWRPDOH1HZ=HDODQG:KLWHUDEELWVJURXS
at 0 (vehicle), 0.4, 1.5, or 4.0 mg axitinib/right eye once on Day 1. Blood samples were 
collected on day 1 pre-dose and 0.5, 1, 2, 4, 12, and 24 hours post-dose.  Axitinib was 
below the LLOQ in all plasma samples except two samples (one animal given 1.5 
mg/right eye [2.11 ng/mL] and one animal given 4.0 mg/right eye [2.28 ng/mL]) from the 
1-hour time point. 
x
In the 4-week single dose rabbit toxicity study with a 26-week recovery phase, CLS-AX
ZDVJLYHQDVDVLQJOHELODWHUDO6&LQMHFWLRQȝ/H\HWRPDOHDQGIHPDOHSLJPHQWHG
Dutch Belted rabbits (5 animals/sex/group) at 0 (vehicle), 0.105, 1.05, or 4.2 mg 
axitinib/eye once on day 1. Blood samples were collected on day 1 pre-dose and 0.25, 
0.5, 1, 6, 12, and 24 hours post-dose, and on days 28, 29 or 30, 60, 91, 120, and 150. 
Axitinib was detected in one plasma sample (one animal given 4.2 mg/ eye [3.05 ng/mL]) 
from the 0.25-hour time point on Day 1. All other samples were below the LLOQ. 
x
In the 2-week single dose monkey toxicity study, CLS-AX was administered as a single 
XQLODWHUDO6&LQMHFWLRQȝ/ULJKWH\HWRPDOHF\QRPROJXVPRQNH\V(2/group) at 0 
(vehicle), 4.0, 6.0, or 8.0 mg axitinib/right eye once on Day 1. Blood samples were 
collected on day 1 pre-dose, and 0.5, 1, 2, 4, 8, and 24 hours post-dose. Axitinib was not 
detected in any plasma samples at any intervals during this study. 
x
In the 4-week single dose monkey toxicity study, CLS-AX was administered as a single 
XQLODWHUDO6&LQMHFWLRQȝ/ULJKWH\HWRPDOHDQGIHPDOHF\QRPROJXVPRQNH\V

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 26 of 60 
CONFIDENTIAL
7.3.
Number of Subjects
The study population will include a maximum of 19 subjects (up to approximately 5 subjects 
each from Cohorts 2, 3 and 4) that successfully complete and exit the Parent study without 
receiving prohibited medication.  Medications prohibited in the Parent study will continue to be 
prohibited in this extension study and are defined in Section 9.5.1.
The expected duration of participation in the extension study is up to 12 weeks from study entry.  
The complete inclusion and exclusion criteria are presented in Section 8. 
7.4.
Treatment Assignment
This is an open-label, non-interventional extension study of the Parent study, CLS1002-101.  
There will be no investigational product dispensed or administered in this study.
7.5.
Criteria for Study Termination
7.5.1.
Early Discontinuation of the Study
The study or parts of the study may be discontinued by the Sponsor, at any time. If the clinical 
study is prematurely terminated, the Sponsor will inform the Investigators and the regulatory 
authorities of the termination and the reason(s) for the termination, and subjects will be asked to 
complete study assessments at Visit 8 (Study Exit, Week 24). The Investigator should promptly 
notify the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) of the 
termination and of the reasons. 
7.5.2.
Suspension of the Study
The study enrollment will be immediately suspended, and no additional subjects will be enrolled 
upon suspension of the Parent study. 
If the clinical study is suspended, the Sponsor will inform the Investigators and the regulatory 
authorities of the suspension and the reason(s) for the suspension. The Investigator should 
promptly notify the IRB or IEC of the suspension and of the reasons. 
Enrollment of subjects into the study will not be restarted until the Sponsor and the Safety 
Monitoring Committee have agreed to the course of action to be taken in the Parent study and the 
IRB/IEC has been notified. 
During the period of suspension of enrollment, provided the Investigator determines that it is in 
the subjects’ best interest to continue in the study, subjects currently enrolled in the extension 
study will continue with the protocol specified visit schedule. The Sponsor’s preference is to 
retain enrolled subjects in the extension study until the final study visit (Visit 8, Week 24).

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 34 of 60 
CONFIDENTIAL
If the pre-defined criteria are met at Visits 6 and/or 7 (Weeks 16 and/or 20), then additional 
therapy consisting of an IVT injection of aflibercept 2 mg (0.05 mL), ranibizumab 0.5 mg (0.05 
mL), bevacizumab 1.25 mg (0.05 mL), or brolucizumab 6 mg (0.05 mL), as determined by the 
Investigator, may be administered; even if additional therapy is given, the subjects will remain in 
the study and will be followed until Visit 8 (Study Exit).  Subjects satisfying the additional 
therapy criteria at Visit 8 (Study Exit) will complete all Visit 8 assessments per protocol, exit the 
study and revert to standard of care as determined by the Investigator. Data of the additional 
therapy administered will be collected whenever possible.
9.5.
Concomitant Medications
Concomitant medications administered for the treatment of existing or new comorbidities, not 
otherwise prohibited by the protocol, will be recorded in the subject’s source document(s) and 
the CRF.
9.5.1.
Prohibited Medications
Subjects must not receive any treatments in the study eye for nAMD or any systemic treatments 
for nAMD not approved in the protocol.  The list of prohibited treatments provided below is not 
intended to be comprehensive, but rather to help guide the Investigator’s medical judgment. In 
cases where a subject presents with a treatment not included on the following list or should there 
be any question on the part of the Investigator, Investigators are encouraged to confer with the 
Medical Monitor for any clarification. 
Use of the following treatments is prohibited at any time during the study: 
x
In cases where there is anticipated need for any of the treatments listed here during the study 
(post Visit 5), or if a subject presents to the Investigator having initiated treatment during the 
study with one of these treatments, it is the responsibility of the Investigator to notify the 
Sponsor immediately. If additional therapy is necessary to treat worsening of nAMD in the study 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 35 of 60 
CONFIDENTIAL
eye and normal standard of care requires additional intervention, the treatment(s) should be 
recorded in the subject’s source document(s) and CRF and should follow the guidelines 
presented for additional therapy criteria. Subjects will not be discontinued from the study 
because of initiation of or change in a prohibited medication.  Any use of a prohibited 
medication will be documented as a protocol deviation. 
9.6.
Treatment Compliance
No study medication will be dispensed or administered to subjects during this extension study;
therefore, an assessment of subject treatment compliance is not applicable.
Study medication will only be administered by trained study Investigators in the Parent study. 
9.7.
Randomization and Masking
This is an open-label study; no masking is necessary. 
This is non-interventional extension study.  Subjects will remain in the dose cohort they 
participated under during the Parent study. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 36 of 60 
CONFIDENTIAL
10.
STUDY DRUG MATERIALS AND MANAGEMENT
This is an open-label, non-interventional extension of the Parent study, CLS1002-101.  No study 
drug will be dispensed or administered to the subjects as part of this protocol.  Additional 
treatments administered during this study will be recorded as concomitant and/or rescue 
medications. Storage of permitted additional treatments should be according to the Prescribing 
Information for the individual treatment(s) and is the responsibility of the Investigator. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 38 of 60 
CONFIDENTIAL
PRN at Visits 6 and/or 7, then IOP will be measured twice: in both eyes before treatment and in 
the study eye 10 to 30 minutes after treatment is administered.  Tonometers must be calibrated 
for accuracy before the first subject visit at that site and according to the manufacturer 
specifications during the study, until the last subject has exited the study at that site. 
11.1.4.
Slit-lamp Biomicroscopy
Slit-lamp biomicroscopy, including magnification, will be performed consistent with standard 
clinical practice. This procedure should be conducted in the same manner for all subjects and 
will include an assessment of each of the following as normal or abnormal: eyelids, pupil and 
conjunctiva, cornea, anterior chamber, iris, and lens. All abnormal findings will be described.  
Slit lamp biomicroscopy will be assessed at all visits.
If the subject’s study eye qualifies for additional therapy at the final visit (Visit 5) of the Parent 
study and receives additional therapy as a result, following enrollment into this extension study, 
then slit-lamp biomicroscopy will be performed in the study eye after treatment is administered
at Enrollment Day or any time during Enrollment Day if administered prior. Slit-lamp 
biomicroscopy will be performed in the study eye at Visits 6 and 7 (Weeks 16 and 20) and in 
both eyes at Visit 8 (Week 24).  If additional therapy is administered PRN at Visits 6 and/or 7, 
then slit-lamp biomicroscopy will be performed twice in the study eye: before treatment and after 
treatment is administered.
11.1.4.1.
Cataract Lens Grading 
If an abnormal finding of cataract is noted during the slit-lamp examination, the cataract should 
be graded for nuclear opalescence, cortical opacity, and posterior subcapsular opacity. Graders 
must verify training on the grading procedures. Cataract classification will be based on the Lens 
Opacities Classification System III (LOCS III) grading scale (Chylack, 1993). Grading should be 
done by the same Investigator, whenever possible, on each subject per research site.
11.1.4.2.
Anterior Chamber Cells
Anterior chamber cells will be assessed clinically using a field size of 1 mm slit beam and using 
a standardized grading scale ranging from 0 to 4+, as defined in Table 5 (SUN, 2005).
Table 5: 
Anterior Chamber Cells Grading Scale
Score
Cells in Field
0
<1
0.5+ 
1-5 
1+ 
6-15 
2+ 
16-25 
3+ 
26-50 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 39 of 60 
CONFIDENTIAL
Table 5: 
Anterior Chamber Cells Grading Scale (Continued)
Score
Cells in Field
4+ 
>50 
11.1.4.3.
Anterior Chamber Flare
Anterior chamber flare will be assessed clinically via slit lamp using a standardized scale ranging 
from 0 to 4+, as defined in Table 6 (SUN, 2005).
Table 6: 
Anterior Chamber Flare Grading Scale
Score
Description
0
None 
1+ 
Faint
2+ 
Moderate (iris and lens details clear)
3+ 
Marked (iris and lens details hazy)
4+ 
Intense (fibrin or plastic aqueous) 
11.1.5.
Indirect Ophthalmoscopy
Indirect ophthalmoscopy should be performed according to the Investigator’s standard 
procedure.  This procedure should be the same for all subjects observed at the Investigator’s site.  
The fundus will be examined thoroughly, and the following variables will be assessed as normal 
or abnormal (including but not limited to): vitreous, retina, choroid, and optic nerve/disc, 
appearance of vessels, and absence of neovascularization. Indirect ophthalmoscopy will be 
assessed at all visits.
If the subject’s study eye qualifies for additional therapy at the final visit (Visit 5) of the Parent 
study and receives additional therapy as a result, following enrollment into this extension study, 
then indirect ophthalmoscopy will be performed in the study eye after treatment is administered 
at Enrollment Day or any time during Enrollment Day if administered prior.  Indirect 
ophthalmoscopy will be performed in the study eye at Visits 6 and 7 (Weeks 16 and 20) and in 
both eyes at Visit 8 (Week 24).  If additional therapy is administered PRN at Visits 6 and/or 7, 
then indirect ophthalmoscopy will be performed twice in the study eye: before treatment and 
after treatment is administered. 
11.1.5.1.
Vitreous Haze
Vitreous haze will be assessed clinically via indirect ophthalmoscopy using a standardized 
photographic scale ranging from 0 to +4, as defined in Table 7 (Nussenblatt, 1985 as modified in 
Lowder, 2011).
Table 7: 
Scale for Determining Degree of Vitreous Haze
Score
Description
0
No inflammation

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 41 of 60 
CONFIDENTIAL
11.1.9.1.
Pregnancy Screen
Urine pregnancy tests will be performed on all females of childbearing potential on Enrollment 
Day and at Visit 8 (Week 24). 
11.2.
Adverse and Serious Adverse Events
11.2.1.
Definition of Adverse Events
11.2.1.1.
Adverse Event (AE)
An AE is the development of an undesirable medical condition or the deterioration of a pre-
existing medical condition in a subject participating in a clinical study, whether or not considered 
to have a causal relationship with the study drug, SCS Microinjector (e.g., endophthalmitis, 
choroidal hemorrhage, etc.) or study procedure (e.g., AEs related to the volume of the injection 
such as transient increase in intraocular pressure).  In clinical studies, an AE can include an 
undesirable medical condition occurring at any time, including baseline or washout periods, even 
if no study treatment has been administered. 
All AEs that occur after any subject has signed informed consent, or during the study 
participation, whether or not they are related to the study drug, SCS Microinjector or study 
procedure, must be recorded on the appropriate form provided.  Each AE is to be evaluated for 
duration, intensity, and causal relationship with the study medication or other factors. 
At every visit, patients should be asked about AEs in an open-ended manner as well as asked 
about the status of any previously reported AEs. 
When possible, a specific disease or syndrome rather than an individual associated sign or 
symptom should be identified by the Investigator and recorded on the form.  If an observed or 
reported sign or symptom is not considered a component of a specific disease or syndrome by the 
Investigator, it should be recorded as a separate AE on the form. 
NOTE:  A significant or unexpected worsening or exacerbation of the condition/indication under 
investigation should be reported as an AE.  However, anticipated day-to-day fluctuations or 
expected progression of the disease under investigation (based upon the Investigator’s clinical 
judgment) are not to be considered AEs. 
11.2.1.2.
Abnormal Clinical Assessments as Adverse Events and Serious Adverse Events
Abnormal assessments (e.g., ocular assessments and vital signs) that are judged by the 
Investigator as clinically significant will be recorded as AEs or SAEs if they meet the definition 
of an AE or SAE.  Abnormal clinical assessments and any clinically significant abnormal 
laboratory findings that are detected during the study or are present at baseline and significantly 
worsen following exposure to study drug are to be reported as AEs or SAEs.  However, clinically 
significant abnormal laboratory findings or other abnormal assessments that are associated with 
the disease being studied, unless judged by the Investigator as more severe than expected for the 
patient’s condition, or that are present at the start of the study and do not worsen, should not be 
reported as AEs or SAEs. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 42 of 60 
CONFIDENTIAL
The Investigator will exercise medical and scientific judgment in deciding whether an abnormal 
laboratory or assessment is clinically significant and if it requires reporting.
11.2.1.3.
Serious Adverse Event (SAE)
An SAE is defined as an AE that meets any of the following criteria:  
x
Results in death.
x
It is immediately life-threatening. NOTE:  The term “life threatening” refers to an 
event in which the patient is at risk of death at the time of the event.  It does not refer 
to an event which hypothetically might have caused death if it was more severe. 
x
It requires in-patient hospitalization or prolongation of existing hospitalization.  
NOTE:  Hospitalization for an elective or procedure planned prior to the signing of 
the informed consent to treat a preexisting condition is not considered an SAE unless 
it results in one of the other outcomes listed in this section.
x
It results in persistent or significant disability or incapacity.
x
Results in a congenital abnormality or birth defect. 
x
It is an important medical event that may jeopardize the patient or may require 
medical intervention to prevent one of the outcomes listed above. 
All SAEs that occur after any subject has signed informed consent, whether or not they are 
related to the study, must be recorded on the forms provided. 
11.2.2.
Evaluating Adverse Events 
11.2.2.1.
Intensity/Severity Grade
The intensity of each AE will be graded using National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) v 4.03.  The criteria can be accessed at: 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_R
eference 5x7.pdf. 
It is important to distinguish between serious and severe AEs. Severity is a measure of intensity 
whereas seriousness is defined by the criteria under Section 11.2.1.3. An AE of severe intensity 
may not be considered serious. 
Grade refers to the intensity of the AE.  The CTCAE displays Grades 1 through 5 with unique 
clinical descriptions of intensity for each AE based on this general guideline: 
Table 8: 
CTCAE Intensity Grades
Grade
Description
Grade 1
Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 43 of 60 
CONFIDENTIAL
Table 8: 
CTCAE Intensity Grades (Continued)
Grade 2
Moderate; minimal, local, or noninvasive intervention indicated; 
limiting age-appropriate instrumental activities of daily living (ADL)
Grade 3
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of the hospitalization indicated; 
disabling; limiting self-care ADL
Grade 4
Life-threatening consequences; urgent intervention indicated 
Grade 5
Death related to AE
11.2.2.2.
Assessment of Causality 
The Investigator is responsible for making an assessment of the causal relationship between the 
AE and the study drug, SCS Microinjector, and/or study procedure based on the available 
information. 
The causal relationship of the AE is assessed using a binary system, and AEs are classified as 
either Related or Unrelated to the study drug, SCS Microinjector, and/or study procedure. 
In assessing this relationship, the Investigator should consider the potential etiologies for the 
observed AE.  An AE may be related to:
x
The study drug(s). 
x
Other concomitant medications.
x
Underlying disease pathology. 
x
A pre-treatment condition.
x
A procedure performed in the course of the study. 
x
Other alternative reason. 
Among the potential etiologies, the Investigator should make a determination based on the most 
likely causal relationship.  The causality assessment provided for an AE or SAE should be 
accompanied by all available supporting evidence, including but not limited to supporting 
laboratory tests, histopathology, history of the presenting event, medical history, temporal 
association, and results of relevant diagnostic procedures. 
11.2.3.
Recording Adverse Events
Adverse events spontaneously reported by the subject and/or in response to an open question 
from the study personnel or revealed by observation will be recorded during the study at the 
investigational site on the CRF.  Information about AEs will be collected from the time of 
signing of the consent form until 30 days after the end of study participation.  Detailed 
information regarding all SAEs should be collected from the signing of the informed consent 
until the end of the study.  SAEs that are considered related to the use of study drug, SCS 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 44 of 60 
CONFIDENTIAL
Microinjector, and/or study procedure by the Investigator may be reported by the Investigator if 
they occur after the end of the study.  The Investigator must continue to follow the patient until 
the SAE has resolved, the condition has become chronic in nature, the condition stabilizes (in the 
case of persistent impairment), the patient experiences a fatal outcome or is lost to follow up. 
The AE term should be reported in standard medical terminology as concisely as possible.  In 
general, the AE recorded should not be a procedure, outcome, or clinical/laboratory 
measurement, but should reflect the event leading to the procedure, outcome, or the cause of the 
clinical/laboratory abnormality, if known.  Whenever possible, AEs should be evaluated and 
recorded as a diagnosis, rather than as individual signs or symptoms.  However, if a definitive 
diagnosis is not possible, the individual signs and symptoms should be recorded.  For each AE, 
the Investigator will evaluate and report the onset (date and time), resolution (date and time), 
intensity, causality, action taken, seriousness, outcome (if applicable), and whether or not it 
caused the patient to discontinue the study.
11.2.4.
Reporting Adverse Events
All AEs (related and unrelated) will be recorded from the signing of consent form until 30 days 
after the end of study participation.  All SAEs occurring during subject participation, and all 
SAEs considered related to the study drug, SCS Microinjector, and/or study procedure and 
discovered by the Investigator at any time after the study should be reported.  All such SAEs 
must be reported to Clearside Biomedical, or its designee, within one 24 hours of the knowledge 
of the occurrence of the event.  The Investigator must complete, sign and date the SAE pages, 
verify the accuracy of the information recorded on the SAE pages with the corresponding source 
documents, and send a copy by email (CLS001Safety@medtrials.com) to Clearside Biomedical, 
or its designee. 
Additional follow-up information, if required or available, should all be emailed or faxed to 
Clearside Biomedical, or its designee, within one business day of receipt.  This information 
should be recorded on a follow-up SAE form and placed with the original SAE information and 
kept with the appropriate section of the CRF and/or study file. 
Clearside Biomedical and/or its designee is responsible for notifying the relevant regulatory 
authorities of certain events.  It is the Principal Investigator’s responsibility to notify and submit 
required safety information to their IRB or IEC.  This information includes, but is not limited to, 
any safety alert letter received from the Sponsor and any SAEs occurring at their investigative 
site.
Investigators will also be notified of all unexpected, serious, drug-related events, SCS 
Microinjector related events and study procedure related events (7/15 Day Safety Reports) that 
occur during the clinical trial.  Each site is responsible for notifying its IRB or IEC of these 
additional SAEs.  A copy of these reports must be retained at the investigative site and file in the 
Trial Master File.
11.2.5.
Follow-up of AEs and SAEs
All AEs and SAEs reported during study conduct must be followed until resolution, or until the 
Investigator assesses them as stable or chronic, the subject withdraws consent, or the subject is 
lost to follow-up. Subjects will be followed for any treatment-related, SCS Microinjector related, 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 45 of 60 
CONFIDENTIAL
and/or study procedure related SAEs reported at the end of participation until the condition 
stabilizes, the event is otherwise explained, the subject is lost to follow-up, the subject withdraws 
consent, or the subject experiences a fatal outcome.
NOTE: “Resolution” means the subject has returned to baseline state of health, or the 
Investigator does not expect any further improvement in the subject’s condition or does not 
expect worsening of the AE. 
For a non-serious AE that is first identified on the last scheduled contact, the event must be 
recorded on the AE CRF with the current status noted, but no further follow-up needs to be 
performed unless deemed necessary by the Investigator or the Sponsor. 
Post-Study SAEs: Investigators are not obligated to actively seek SAE information in former 
study participants; however, any new SAE reported by the subject to the Investigator that occurs 
after the last scheduled contact and is determined by the Investigator to be associated with the 
use of study drug, the use of the SCS Microinjector, and/or study procedure, should be reported 
to the Sponsor. The Investigator should follow related SAEs identified after the last scheduled 
contact until the event has resolved or stabilized or the subject is lost to follow-up. 
11.2.6.
Exposure in utero During Clinical Trials
The Sponsor must be notified of any patient who becomes pregnant while participating in the 
clinical trial.  Although pregnancy is not considered an AE, all pregnancies must be followed to 
conclusion to determine their outcome.  This information is important for both drug safety and 
public health concerns.  It is the responsibility of the Investigator or designee to report any 
pregnancy in a subject that occurs during the study.  Should a patient in the study become 
pregnant, the site must complete the Exposure in utero reporting form.  Notification should be 
made within 24 hours of awareness of the event. 
It is the responsibility of the Investigator, or designee, to report any pregnancy and the 
anticipated date of birth that occurs while receiving, or within 30 days of discontinuing the study 
drug, via the Exposure in utero reporting form.  If the pregnancy is to be terminated, the 
anticipated date of termination should be provided. 
If it is the partner, rather than the subject, who is found to be pregnant, after obtaining the 
partner’s consent, the Exposure in utero reporting form should be completed with the anticipated 
date of birth/termination and details regarding the partner should be entered in the narrative 
section of the form. 
The patient/partner should be followed by the Investigator until completion of the pregnancy.  If 
the pregnancy ends for any reason before the anticipated date of birth/termination, the 
Investigator should notify the Sponsor.  At the completion of the pregnancy, the Investigator will 
document the outcome of the pregnancy.  If the outcome of the pregnancy meets criteria for 
immediate classification as an SAE (i.e., post-partum complications, spontaneous abortion, 
miscarriage, still birth, neonatal death, or congenital anomaly (even of an aborted fetus), the 
Investigator should follow the procedures for reporting an SAE.  Note, elective termination of a 
pregnancy would not meet criteria as an SAE and in these cases a follow up pregnancy report 
should be provided by the Investigator. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 46 of 60 
CONFIDENTIAL
11.2.7.
Complaint Handling
Clearside collects product complaints on study drugs and SCS Microinjectors used in clinical 
studies in order to ensure the safety of study participants, monitor quality, and to facilitate 
process and product improvements. 
All product complaints associated with material packaged, labeled, and released by Clearside 
will be reported via product complaint forms. 
The complainant (the Investigator, site staff, etc.) or his/her designee is responsible for handling 
the following aspects of the product complaint process in accordance with the instructions 
provided for this study: 
x
Recording a complete description of the product complaint reported and any 
associated AEs using the study-specific complaint forms provided for this purpose. 
x
Emailing the completed product complaint form within 48 hours to Clearside at the 
following address:  complaints.QA@clearsidebio.com.
x
Returning a Study drug/ SCS Microinjector  for investigation when directed by 
Clearside.

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 48 of 60 
CONFIDENTIAL
safety, including ocular adverse events, will be presented for the study eye and separately for the 
fellow-eye.
Safety endpoints are provided in Section 7.2 .  Additional endpoints will be described in the 
statistical analysis plan.
12.5.1.
Schedule of Analyses
The study duration will consist of 12 weeks of additional follow-up after the subject has 
completed participation in the Parent study CLS1002-101. 
Analyses of study data for evaluating Cohort 2 will be performed after all subjects enrolled into 
the dose cohort have completed Visit 8 (Week 24) of the extension (or have been discontinued 
from the study prior to this visit) and the data has been locked. 
Analyses of study data for evaluating Cohort 3 and for comparison between Cohorts 2 and 3 will 
be performed after all subjects enrolled into Cohort 3 have completed Visit 8 (Week 24) of the 
extension (or have been discontinued from the study prior to this visit) and the data has been 
locked. 
Analyses of study data for evaluating Cohort 4 and for comparison between all dose cohorts will 
be performed after all subjects enrolled into Cohort 4 have completed Visit 8 (Week 24) of the 
extension (or have been discontinued from the study prior to this visit) and the data has been 
locked. 
12.5.2.
Safety Analysis 
The summary of adverse events (and SAEs) will be limited to TEAEs.  Treatment-emergent 
adverse events are defined as an event that emerges during treatment with CLS-AX (Visit 2, Day 
1) having been absent pre-treatment or worsens relative to the pre-treatment state.
For summarizing adverse events, each reported adverse event term will be coded to a preferred 
term and its corresponding system organ class (SOC) using the Medical Dictionary for 
Regulatory Activities (MedDRA) coding dictionary.  Summary tables will be presented by dose 
cohort. 
Summary tables of TEAEs will be produced for the following categories divided into Study Eye 
TEAEs, Fellow Eye TEAEs, ocular TEAEs, non-ocular TEAEs and overall TEAEs, grouped by 
SOC and preferred term:
x
All TEAEs.
x
All treatment-related TEAEs.
x
All TEAEs leading to study discontinuation. 
x
All SAEs.
x
All treatment-related SAEs.
x
All TEAEs leading to death.
For each summary, adverse events will be summarized by presenting the number and percentage 
of subjects reporting each event at least once, and the total number of events reported. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 49 of 60 
CONFIDENTIAL
12.5.3.
Secondary Safety Analyses 
Secondary safety analyses will be performed on all subjects in the Safety Population.  Ocular 
safety will be assessed by evaluating IOP, BCVA and outcomes obtained from the slit-lamp 
biomicroscopy, indirect ophthalmoscopy, SD-OCT, fundus photography and angiography 
examinations.  Summaries will be provided for each dose cohort for the Study eye. 
Systemic safety will be assessed by evaluating vital signs and concomitant medications.  
Summaries will be provided for each dose cohort. 
12.5.4.
Subgroup Analysis
No subgroup analyses are planned. 
12.5.5.
Interim Analysis
Analysis of all safety data will be performed at the completion of each dose cohort.  No formal 
statistical testing will be conducted.  All inferential statistics will be for descriptive purposes 
only; therefore, no adjustments will be made to the type 1 error rate to account for multiple 
analyses of the data.
12.5.6.
Pharmacodynamic Analysis 
Not applicable.
12.5.7.
Pharmacokinetic Analysis
Not applicable.
12.5.8.
Procedure for Accounting for Missing Data
Any missing, unused, or spurious data will be noted in the final clinical study report. 
No imputation for missing data will be used in the Safety Populations. 
Algorithms for handling partial or incomplete dates for adverse events, concomitant medications, 
and diagnoses will be defined in the statistical analysis plan. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 50 of 60 
CONFIDENTIAL
13.
DIRECT ACCESS TO SOURCE DATA/DOCUMENTS
13.1.
Study Monitoring
During the study, a monitor from Clearside Biomedical, Inc. or representative will have regular 
contacts (oral, written, onsite, virtual) with the investigational site, for the following:
x
Provide information and support to the Investigator (s). 
x
Confirm that facilities and personnel continue to remain acceptable. 
x
Confirm that the investigational team is adhering to applicable standards for 
conducting trials (e.g., ICH, GCP) the protocol, that data are being accurately 
recorded in the case report forms.
x
Perform source data verification.  This includes a comparison of the data in the case 
report forms with the subject’s medical records at the hospital or practice, and other 
source documents relevant to the study.  This will require direct access to all original 
records for each patient (e.g., clinic charts).
x
Record and report any protocol deviations not previously recorded in the CRF or 
reported to IRB and/or Clearside Biomedical, Inc. or designee. 
x
Confirm AEs and SAEs have been properly documented on CRFs and confirm any 
SAEs have been forwarded to Clearside Biomedical, Inc, or designee, and those 
SAEs that met criteria for reporting have been forwarded to the IRB/IEC.
The monitor will be available between visits if the Investigator(s) or other staff needs 
information or advice. 
13.2.
Audits and Inspections
Authorized representatives of Clearside Biomedical, Inc, a regulatory authority, an Independent 
Ethics Committee, or an Institutional Review Board may visit the site to perform audits or 
inspections, including source data verification.  The purpose of a Clearside Biomedical, Inc audit 
or inspection is to systematically and independently examine all study-related activities and 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported according to the protocol, Good Clinical Practice guidelines of 
the International Conference on Harmonization, and any applicable regulatory requirements.  
The Investigator should contact Clearside Biomedical, Inc immediately if contacted by a 
regulatory agency about an inspection. 
13.3.
Institutional Review Board (IRB)
The Principal Investigator must obtain IRB/IEC approval for the investigation.  Initial IRB/IEC 
approval, and all materials approved by the IRB/IEC for this study including the subject consent
form and recruitment materials must be maintained by the Investigator and made available for 
inspection. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 51 of 60 
CONFIDENTIAL
14.
QUALITY CONTROL AND QUALITY ASSURANCE
During study conduct, Clearside or it’s agent(s) or designee(s) will conduct periodic monitoring 
visits to ensure the protocol and Good Clinical Practice (GCPs) are being followed.  The 
progress of the study will also be monitored by written, e-mail, and telephone communications 
between personnel at the study site and the Sponsor and its agent(s) or designee(s). The
Investigator will allow Sponsor monitors, or designee(s), direct access to inspect all CRFs, 
subject records (source documents), signed Informed Consent Forms, study records, and 
regulatory files related to the study to perform verification and to confirm that the data recorded 
on CRFs is accurate.
The study site may be subject to review by the Institutional Review Board (IRB)/Independent 
Ethics Committee (IEC), and/or to quality assurance audits performed by Clearside, or 
companies working with or on behalf of Clearside, and/or to inspection by appropriate regulatory 
authorities.
It is important that the Investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits, or inspections and that sufficient time is devoted to the 
process.

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 52 of 60 
CONFIDENTIAL
15.
ETHICS 
15.1.
Ethics Review
The final study protocol, including the final version of the Informed Consent Form, and other 
relevant documents, e.g., recruitment advertisements, if applicable, must be approved or given a 
favorable opinion in writing by an IRB or IEC, as appropriate.  The Investigator must submit 
written approval to Clearside Biomedical, Inc, or designee, before he or she can enroll any 
subject into the study. 
The Principal Investigator is responsible for informing the IRB or IEC of any amendment to the 
protocol in accordance with local requirements.  In addition, the IRB or IEC must approve all 
advertising used to recruit patients for the study.  The protocol must be re-approved by the IRB 
or IEC upon receipt of amendments and annually, as local regulations require. 
The Principal Investigator is also responsible for providing the IRB with reports of any 
reportable serious adverse drug reactions from any other study conducted with the study drug.  
Clearside Biomedical, Inc will provide this information to the Principal Investigator.
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB 
or IEC according to local regulations and guidelines. 
All correspondence with the IRB/IEC should be retained in the Investigator File. 
15.2.
Ethical Conduct of the Study
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/GCP, applicable local regulatory 
requirements and laws.  In addition, the study will be conducted in accordance with the protocol. 
The Investigator will inform Clearside and/or its agent(s) immediately of any urgent safety 
measures taken by the Investigator to protect the study subjects against any immediate hazard, 
and of any serious breaches of this protocol or of ICH GCP that the Investigator becomes aware 
of.
15.3.
Written Informed Consent
The Principal Investigator(s) at each center will be responsible for ensuring that the patient is 
given full and adequate oral and written information about the nature, purpose, possible risk, and 
benefit of the study. Subjects must also be notified that they are free to discontinue from the 
study at any time. The informed consent document must be in compliance with ICH GCP, local 
regulatory requirements, and legal requirements. The informed consent document used in this 
study, and any changes made during the course of the study, must be prospectively approved by 
both the IRB/IEC and Clearside and/or its agent(s) before use.  The subject should be given the 
opportunity to ask questions and allowed time to consider the information provided. 
The subject’s signed and dated informed consent must be obtained before conducting any study 
procedures. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 53 of 60 
CONFIDENTIAL
The Principal Investigator(s) must maintain the original, signed Informed Consent Form.  A copy 
of the signed Informed Consent Form must be given to the subject. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 54 of 60 
CONFIDENTIAL
16.
DATA HANDLING AND RECORDKEEPING
16.1.
Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or an 
electronic data record or both, depending on the data collection method used in this study. 
A CRF is required and should be completed for each included subject.  The completed original 
CRFs are the sole property of Clearside and should not be made available in any form to third 
parties, except for authorized representatives of Clearside or appropriate regulatory authorities, 
without written permission from Clearside.
The Investigator has ultimate responsibility for the collection and reporting of all clinical, safety 
and laboratory data entered on the CRFs and any other data collection forms (source documents) 
and ensuring that they are accurate, authentic / original, attributable, complete, consistent, 
legible, timely (contemporaneous), enduring and available when required. 
16.2.
Inspection of Records
Clearside Biomedical, Inc or its designee will be allowed to conduct site visits to the 
investigation facilities for the purpose of monitoring any aspect of the study.  The Investigator 
agrees to allow the monitor to inspect drug storage area(s) to confirm continued acceptability and 
inventory of additional therapy and rescue medication(s), subject charts and study source 
documents, and any other records relative to study conduct. 
16.3.
Retention of Records
The Principal Investigator must maintain all records relating to the study for a period of 2 years 
after the last marketing application approval, or if not approved 2 years following the 
discontinuance of the test article for investigation.  If it becomes necessary for Clearside 
Biomedical, Inc or the Regulatory Authority to review any documentation relating to the study, 
the Investigator must permit access to such records.

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 55 of 60 
CONFIDENTIAL
17.
FINANCING AND INSURANCE
17.1.
Finance
This study is supported by Clearside Biomedical, Inc. 
17.2.
Insurance
Documentation of product liability insurance is on file at Clearside and is available upon request. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 56 of 60 
CONFIDENTIAL
18.
PUBLICATION POLICY
All information concerning CLS1002-102 and the operations of Clearside Biomedical, Inc., such 
as patent, applications, formulas, manufacturing processes, basic scientific data or formulation 
information not previously published, are considered CONFIDENTIAL and shall remain the sole 
property of Clearside Biomedical Inc. The Investigator agrees to use this information only in 
accomplishing this study and will not use it for other purposes without the written consent of 
Clearside Biomedical Inc. The institutions and Investigators participating in this study shall have 
no right to publish or present the results of this study without the prior written consent of 
Clearside Biomedical, Inc.

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 57 of 60 
CONFIDENTIAL
19.
REFERENCES
Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: 
etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003 May-Jun;48(3): 257-
93.
%XVEHH%*+R$&%URZQ'0+HLHU-66XxHU,-/L=5XELR5*/DL3+$5%25Study 
Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with 
subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013 May;120(5): 
1046-1056. 
Cabral T, Lima LH, Mello LGM, Polido J, Correa ÉP, Akiyoshi Oshima, Jimmy Duong, Pedro 
Serracarbassa, Caio V. Regatieri, Vinit B. Mahajan, Rubens Belfor. Bevacizumab injection in 
patients with neovascular age-related macular degeneration increases angiogenic biomarkers. 
Ophthalmol Retina. 2018 Jan; 2(1): 31–37. doi:10.1016/j.oret.2017.04.004. 
Chylack LT, Wolfe JK, Singer DM, Leske MC, Bullimore MA, Bailey IL, Friend J, Wu SY. The 
lens opacities classification system III. The longitudinal study of cataract study group. Archives 
of ophthalmology. 1993 Jun; 111(6): 831-836. 
Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual Acuity Outcomes and Anti-Vascular 
Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration 
Patients: A Real-World Analysis of 49,485 Eyes. Ophthalmol Retina. 2020 Jan; 4(1): 19-30 
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group 
Writing Committee: Maureen G. Maguire, PhD, Daniel F. Martin, MD, Gui-shuang Ying, PhD, 
Glenn J. Jaffe, MD, Ebenezer Daniel, MBBS, PhD, Juan E. Grunwald, MD, Cynthia A. Toth, 
MD, Frederick L. Ferris III, MD, Stuart L. Fine, MD. Five-Year Outcomes with Anti-Vascular 
Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The 
Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016 
Aug;123(8): 1751-1761. 
Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, Kempen J, Taylor HR, 
Mitchell P. Eye Diseases Prevalence Research Group. Causes and prevalence of visual 
impairment among adults in the United States. Arch Ophthalmol. 2004 Apr;122(4): 477-85. 
Flaxel CJ, MD, Adelman RA, MD, MPH, MBA, FACS, Bailey ST, MD, Fawzi A, MD, Lim JI, 
MD, Vemulakonda GA, MD, Ying G, MD, PhD. Age-Related Macular Degeneration Preferred 
Practice Pattern®. Ophthalmology. 2020 Jan;127(1): 1-65. 
Giddabasappa A, Lalwani K, Norberg R, Gukasyan HJ, Paterson D, Schachar RA, Rittenhouese 
K, Klamerus K, Mosyak L, Eswaraka J. Axitinib inhibits retinal and choroidal 
neovascularization in in-vitro and in-vivo models. Exp Eye Res.  2016 Apr, 145: 373-379. 
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A. 
Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, 
Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U. Intravitreal aflibercept (VEGF 
trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12): 2537-
2548.

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 58 of 60 
CONFIDENTIAL
Hu-/RZH'=RX+<*UD]]LQL0/+DOOLQ0(:LFNPDQ*5$PXQGVRQ.&KHQ-+
Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O’Connor P, 
Shalinsky DR, Bender SL. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-
013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor 
tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008 Nov 15; 14(22): 7272-7283. 
INLYTA (axitinib) tablets for oral administration [package insert]. New York, NY: Pfizer Labs 
(Pfizer, Inc); 2018. 
Kang S, Roh CR, Cho WK, Park KC, Yang KJ, Choi HS, So-Hee K, Roh YJ. Antiangiogenic 
effects of Axitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on 
laser-induced choroidal neovascularization in mice. Curr Eye Res. 2013 Jan; 38(1): 119-127. 
/LHX&+7UDQ+-LDQJ=40DR02YHUPDQ0-/LQ((QJ&0RUULV-(OOLV/+H\Pach 
JV, Kopetz S. The Association of alternate VEGF ligands with resistance to anti-VEGF therapy 
in metastatic colorectal cancer. PLoS ONE. 2013 Oct 15; 8(10): e77117. 
Lowder C, Belfort R, Lightman S, et al. Dexamethasone Intravitreal Implant for Noninfectious 
Intermediate or Posterior Uveitis. Arch Ophthalmol. 2011 May;129(5): 545-553. 
Nakano A, Nakahara T, Mori A, Ushikubo H, Sakamoto K, Ishii K. Short-term treatment with 
VEGF receptor inhibitors induces retinopathy of prematurity-like abnormal vascular growth in 
neonatal Rats. Exp Eye Res. 2016 Feb; 143: 120-131. 
Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory 
activity in intermediate and posterior uveitis. Ophthalmology. 1985 Apr;92(4): 467– 471. 
Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke II DW, Williams GA. 
Real-world vision in age-related macular degeneration patients treated with single anti-VEGF 
drug type for 1 year in the IRIS Registry. Ophthalmology. 2018 Apr;125(4): 522-528. 
RiqueOPH0/&DPSRVဨ0ROOR()HUQiQGH]ဨ6iQFKH]/7RSLFDOD[LWLQLELVDSRWHQWLQKLELWRURI
corneal neovascularization. Clinical and Experimental Ophthalmology 2018; 46: 1063–1074.  
5RIDJKD6%KLVLWNXO5%%R\HU'66DGGD65=KDQJ.6(9(1-UP Study Group. Seven-year 
outcomes in ranibizumab-WUHDWHGSDWLHQWVLQ$1&+250$5,1$DQG+25,=21D
multicenter cohort study (SEVEN-UP). Ophthalmology. 2013 Nov;120(11): 2292-9. 
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, 
Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo 
<$QGHUHVL06RZDGH2=HLW]21RUHQEHUJ&6DQGEULQN5+HLHU-6,QWUDYLWUHDODIOLEHUFHSW
injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW 
studies. Ophthalmology. 2014 Jan;121(1): 193-201. 
6LQJHU0$$ZK&&6DGGD6)UHHPDQ:5$QWRV]\N$1:RQJ37XRPL/+25,=21DQ
open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-
related macular degeneration.  Ophthalmology. 2012 Jun;119(6): 1175-83. 
SUN Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results 
from the first international workshop. Am J Ophthalmol. 2005 Sep;140(3): 509-516. 

CLS-AX (axitinib injectable suspension) 
 
Clearside Biomedical, Inc.
CLS1002-102 (Version 2.0) 
Clinical Protocol
Version Date: 26 January 2022 
Page 59 of 60 
CONFIDENTIAL
The Eye Diseases Prevalence Research Group. Prevalence of Age-Related Macular Degeneration 
in the United States. Arch Ophthalmol. 2004 Apr;122(4): 564-572. 
Thiele S, Liegl RG, König S, Siedlecki J, Langer J, Eibl K, Haritoglou C, Kampik A, Kernt M. 
Multikinase Inhibitors as a New Approach in Neovascular Age-Related Macular Degeneration 
(AMD) Treatment: In Vitro Safety Evaluations of Axitinib, Pazopanib and Sorafenib for 
Intraocular Use. Klin Monbl Augenheilkd 2013 Mar; 230(3): 247-254. 
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-
related macular degeneration and disease burden projection for 2020 and 2040: a systematic 
review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106-16. 
Yuan X, Marcano DC, Shin CS, Hua X, Isenhart LC, Pflugfelder SC, Acharya G. Ocular drug 
delivery nanowafer with enhanced therapeutic efficacy. ACS Nano. 2015 Feb 24;9(2): 1749-58.